ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Recommendation of “Buy” from Brokerages

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been assigned a consensus rating of “Buy” from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $77.71.

A number of research analysts have recently weighed in on the stock. Truist Financial raised their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research note on Tuesday, October 22nd. HC Wainwright reiterated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective on the stock. Piper Sandler assumed coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price on the stock. Finally, Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. This trade represents a 4.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the sale, the chief executive officer now owns 370,378 shares of the company’s stock, valued at $21,478,220.22. The trade was a 8.29 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,381 shares of company stock worth $2,441,556. 12.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ANIP. KBC Group NV lifted its stake in ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after acquiring an additional 600 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares during the period. XTX Topco Ltd purchased a new stake in shares of ANI Pharmaceuticals in the second quarter worth approximately $207,000. HighTower Advisors LLC acquired a new stake in shares of ANI Pharmaceuticals during the third quarter worth approximately $222,000. Finally, Profund Advisors LLC purchased a new position in ANI Pharmaceuticals during the second quarter valued at approximately $225,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Down 0.1 %

Shares of NASDAQ ANIP opened at $58.64 on Tuesday. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of -106.62 and a beta of 0.73. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $70.81. The firm has a 50-day moving average price of $56.25 and a 200 day moving average price of $58.71. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same period last year, the firm earned $1.05 EPS. Equities research analysts anticipate that ANI Pharmaceuticals will post 3.86 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.